,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'breast', 'destinybreast04']
a few hours before #asco22 plenary session, out in results of #destinybreast04 trial showing impressive survival improvement (doubling of pfs with hr 0.51 and major os gain) with #trastuzumabderuxtecan in #her2-low advanced #breastcancer 
Associate Professor at @UniGenova & Medical Oncologist at @SanMartino_Ge. Prior @myESMO fellow. #BreastCancer #Fertility. Big fan of @sampdoria & @giroditalia.